Hanmi Pharm established a $730 million worth license contract for an anticancer new drug with Boehringer

Published: 2015-07-30 14:11:03

Updated: 2015-07-30 14:24:00

Hanmi Pharm(President Kwan-soon Lee) announced on the 28^th that it established a license contract for its targeted lung cancer new drug(HM61713), which is being developed on its own, with Boehringer Ingelheim.

Under the contract, Boehringer Ingelheim is now owning the right to exclusively sell HM61713 in every region except for Korea, China and Hong Kong.

Moreover, Hanmi Pharm will receive th...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.